• LAST PRICE
    1.9700
  • TODAY'S CHANGE (%)
    Trending Down-0.0400 (-1.9900%)
  • Bid / Lots
    1.9600/ 50
  • Ask / Lots
    1.9700/ 2
  • Open / Previous Close
    2.0000 / 2.0100
  • Day Range
    Low 1.9700
    High 2.0000
  • 52 Week Range
    Low 0.7500
    High 13.0100
  • Volume
    4,466
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.01
TimeVolumePRDS
09:32 ET3962
09:35 ET3542
09:37 ET8002
09:48 ET2502
11:43 ET15191.97
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPRDS
Pardes Biosciences Inc
124.1M
-1.3x
---
United StatesGNTA
Genenta Science SPA
113.3M
-29.1x
---
United StatesATMS
Artemis Therapeutics Inc
123.6M
-39.2x
---
United StatesGMDA
Gamida Cell Ltd
124.6M
-1.2x
---
United StatesIMRA
Imara Inc
123.6M
-2.8x
---
United StatesMTNB
Matinas BioPharma Holdings Inc
123.4M
-5.2x
---
As of 2023-02-03

Company Information

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics to improve the lives of patients suffering from life-threatening diseases. Its lead candidate, PBI-0451, is in clinical development and is developed to treat and prevent coronaviral (CoV) infections. It has built a discovery platform designed to target reactive nucleophiles. The Company by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, has discovered and is developing product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. The Company's lead product candidate, PBI-0451, inhibits the main coronaviral cysteine protease, or Mpro, a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. The PBI-0451 product candidate is in Phase I clinical development.

Contact Information

Headquarters
2173 Salk Avenue, Suite 250, Pmb#052CARLSBAD, CA, United States 92008
Phone
415-649-8758
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer
Thomas Wiggans
Chief Financial Officer
Heidi Henson
Director
John Pottage
Director
Laurie Smaldone Alsup
Independent Director
Deborah Autor

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$124.1M
Revenue (TTM)
$0.00
Shares Outstanding
61.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.48
Book Value
$4.27
P/E Ratio
-1.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.